It’s finally happening. The first new class of antidepressant medication in 30 years. On February 12, the FDA advisory committee gave it’s approval to esketamine to be marketed under the trade name SpravatoTM by Janssen Pharmaceutical Companies of Johnson & Johnson for TRD and for MDD with an imminent risk of suicide.1

Here is a summary of what you need to know:

  1. Johnson & Johnson. FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression. https://www.jnj.com/fda-advisory-committee-recommends-approval-of-spravatotm-esketamine-nasal-spray-ciii-for-adults-with-treatment-resistant-depression. accessed February 25, 2019.
  2. Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psych. 2018;175(12):1205-1215.

Find us

21110 Biscayne Blvd., Suite 304
Aventura, FL 33180

Valet parking available

305-932-5500  •  305-935-0466 Fax
Mon-Thur 8am-6pm and Fri 8am-5pm
Closed for lunch 1pm-2pm daily
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram